This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Transplantation  • Transplantation, Other  • Oncology  • Breast Cancer  • Alert me on articles by topic

William J. Gradishar, MD

JAMA. 1999;282:1378-1380.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The rapid transfer of medical technology from academic research institutions into the medical community at large is perhaps not better exemplified than with the widespread use of high-dose chemotherapy (HDC) and peripheral blood stem cell transplantation (PBSCT) as treatments for breast cancer during the late 1980s and the 1990s.¹ With better supportive care measures, particularly use of hematopoietic growth factors, morbidity and mortality due to HDC administration dramatically declined, and the length of hospital stays needed for patients to recover from treatment effects decreased significantly.¹ Peripheral blood stem cells proved to be more reliable and "patient-friendly" in ensuring engraftment, compared with autologous bone marrow.¹ Subsequent data from pilot or feasibility trials in patients with metastatic disease showed that HDC-PBSCT improved tumor response rates compared with conventional-dose chemotherapy.² Many medical oncologists, patients, and advocates were quick to assume that HDC-PBSCT was superior to other therapies used to . . . [Full Text of this Article]

Author Affiliations: Breast Medical Oncology, Lynn Sage Breast Cancer Program, Robert H. Lurie Comprehensive Cancer Center, and Division of Hematology/Oncology, Northwestern University Medical School, Chicago, Ill.

RELATED ARTICLE

Factors Correlated With Progression-Free Survival After High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Metastatic Breast Cancer
Philip A. Rowlings, Stephanie F. Williams, Karen H. Antman, Karen K. Fields, Joseph W. Fay, Elizabeth Reed, Corey J. Pelz, John P. Klein, Kathleen A. Sobocinski, M. John Kennedy, Cesar O. Freytes, Philip L. McCarthy, Jr, Roger H. Herzig, Edward A. Stadtmauer, Hillard M. Lazarus, Andrew L. Pecora, Jacob D. Bitran, Steven N. Wolff, Robert Peter Gale, James O. Armitage, William P. Vaughan, Gary Spitzer, and Mary M. Horowitz
JAMA. 1999;282(14):1335-1343.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

From the Clinics to the Courts: The Role Evidence Should Play in Litigating Medical Care
Morreim
Journal of Health Politics, Policy and Law 2001;26:409-428.
 

Defining and Describing Benefit Appropriately in Clinical Trials
King
J Law Med Ethics 2000;28:332-343.
 

Quality of Life: Erosions and Opportunities Under Managed Care
Morreim
J Law Med Ethics 2000;28:144-158.
 

Stem Cell Transplantation for Metastatic Breast Cancer?
JWatch General 1999;1999:2-2.
FULL TEXT